ZURA BIO LTD CLASS A (ZURA)
Health Care · Clinical-stage immunology and antibody therapeutics · NASDAQ
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current therapies leave patients with inadequate disease control.
What ZURA BIO LTD CLASS A does
Zura Bio is a clinical-stage biotechnology company developing novel monoclonal and bispecific antibodies for autoimmune and inflammatory diseases with significant unmet medical need. The company has in-licensed three product candidates: tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; crebankitug (ZB-168), targeting IL-7 receptor alpha; and torudokimab (ZB-880), targeting IL-33. Zura is currently conducting two global Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis.
Themes: ["Autoimmune and inflammatory diseases","Monoclonal antibodies / immunotherapy","Bispecific antibody therapy","Clinical-stage biotech","Unmet medical need in immunology"]
Fundamentals
- Price$5.51 as of 2026-07-09 close
- Market cap$497M as of 2026-07-10
- 1-year return+308.1% as of 2026-07-09 close
- ROE-54.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.08 as of 2026-07-10
Key risks (from latest filing)
["Early-stage development with no completed Phase 2 or Phase 3 clinical trials and no approved products; significant risk that product candidates fail to demonstrate clinical benefit or regulatory approval","Substantial ongoing capital requirements; company has incurred significant losses since inception and expects continued losses, requiring additional financing to sustain operations and advance development programs","Reliance on third-party contract development and manufacturing organizations, contract research organizations, and clinical trial sites; inability to renew contracts or disputes with vendors could delay or impair product development"]
Competitors & peers
- Gossamer Bio (GOSS)
- Kiniksa Pharmaceuticals (KNSA)
- Aurinia Pharmaceuticals (AUPH)
- Coherus BioSciences (CHRS)
- Aduro Biotech (ADRO)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.